

# Guido Cavaletti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9157853/guido-cavaletti-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

351  
papers

13,732  
citations

62  
h-index

99  
g-index

405  
ext. papers

15,781  
ext. citations

5.3  
avg, IF

6.3  
L-index

#	Paper	IF	Citations
351	Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database.. <i>Neurological Sciences</i> , <b>2022</b> , 1	3.5	4
350	Prospectively Assessing Serum Neurofilament Light Chain Levels As A Biomarker Of Paclitaxel-Induced Peripheral Neurotoxicity In Breast Cancer Patients.. <i>Journal of the Peripheral Nervous System</i> , <b>2022</b> ,	4.7	1
349	Making Connections: Mesenchymal Stem Cells Manifold Ways to Interact with Neurons. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 5791	6.3	0
348	Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain.. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 817236	5.6	1
347	Clinical and preclinical features of eribulin-related peripheral neuropathy. <i>Experimental Neurology</i> , <b>2021</b> , 348, 113925	5.7	1
346	Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?. <i>Neurotherapeutics</i> , <b>2021</b> , 1	6.4	1
345	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. <i>Supportive Care in Cancer</i> , <b>2021</b> , 1	3.9	2
344	Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. <i>Neuroscience Letters</i> , <b>2021</b> , 749, 135739	3.3	5
343	The neurophysiological lesson from the Italian CIDP database. <i>Neurological Sciences</i> , <b>2021</b> , 1	3.5	1
342	Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect. <i>Scientific Reports</i> , <b>2021</b> , 11, 10523	4.9	0
341	Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2021</b> , 92, 1080-1088	5.5	0
340	Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	0
339	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , <b>2021</b> , 97, e660-e672	6.5	6
338	Genetic factors influencing the development of vincristine-induced neurotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 215-226	5.5	5
337	High-Spatial-Resolution Three-dimensional Imaging of Human Spinal Cord and Column Anatomy with Postmortem X-ray Phase-Contrast Micro-CT. <i>Radiology</i> , <b>2021</b> , 298, 135-146	20.5	7
336	Alterations of gut microbiota composition in post-finasteride patients: a pilot study. <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 44, 1263-1273	5.2	12
335	Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 620-629	6	9

334	Electrophysiological Assessments in Peripheral Nerves and Spinal Cord in Rodent Models of Chemotherapy-Induced Painful Peripheral Neuropathy. <i>Neuromethods</i> , <b>2021</b> , 133-161	0.4	0
333	Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	7
332	Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
331	Clinical and biochemical markers in CIPN: A reappraisal. <i>Revue Neurologique</i> , <b>2021</b> , 177, 890-907	3	4
330	Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. <i>Brain</i> , <b>2021</b> ,	11.2	10
329	Nerve pathology in animal models of neuropathies. <i>Journal of the Peripheral Nervous System</i> , <b>2021</b> , 26 Suppl 2, S61-S68	4.7	
328	Assessment of Neurofilament Light Protein as a Serum Biomarker in Rodent Models of Toxic-Induced Peripheral Neuropathy. <i>Neuromethods</i> , <b>2021</b> , 267-275	0.4	
327	Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 103575	7	3
326	Exercise and Neuropathy: Systematic Review with Meta-Analysis.. <i>Sports Medicine</i> , <b>2021</b> , 1	10.6	1
325	Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review. <i>Lancet Haematology</i> , <b>2020</b> , 7, e408-e417	14.6	6
324	Impact of environmental factors and physical activity on disability and quality of life in CIDP. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2683-2691	5.5	3
323	Design and Synthesis of Chitosan-Gelatin Hybrid Hydrogels for 3D Printable Models. <i>Frontiers in Chemistry</i> , <b>2020</b> , 8, 524	5	14
322	Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	15
321	Metabolomics markers in Neurology: current knowledge and future perspectives for therapeutic targeting. <i>Expert Review of Neurotherapeutics</i> , <b>2020</b> , 20, 725-738	4.3	1
320	SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 78, 161-163	3.9	9
319	Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. <i>Journal of Neuroimmunology</i> , <b>2020</b> , 345, 577288	3.5	7
318	Exploring the RC-106 Chemical Space: Design and Synthesis of Novel ()-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents. <i>Frontiers in Chemistry</i> , <b>2020</b> , 8, 495	5	1
317	Sex dimorphism in an animal model of multiple sclerosis: Focus on pregnenolone synthesis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2020</b> , 199, 105596	5.1	4

316	Establishing sample-preparation protocols for X-ray phase-contrast CT of rodent spinal cords: Aldehyde fixations and osmium impregnation. <i>Journal of Neuroscience Methods</i> , <b>2020</b> , 339, 108744	3	6
315	RELEVANCE OF DIAGNOSTIC INVESTIGATIONS IN CHRONIC INFLAMMATORY DEMYELINATING POLIRADICULONEUROPATHY: DATA FROM THE ITALIAN CIDP DATABASE. <i>Journal of the Peripheral Nervous System</i> , <b>2020</b> , 25, 152	4.7	7
314	Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. <i>Archives of Toxicology</i> , <b>2020</b> , 94, 2517-2522	5.8	20
313	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. <i>Blood</i> , <b>2020</b> , 136, LBA-5-LBA-5	2.2	1
312	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 4601-4606	15.9	22
311	Protective Effect of Human Mesenchymal Stem Cells on the Survival of Pancreatic Islets. <i>International Journal of Stem Cells</i> , <b>2020</b> , 13, 116-126	3	2
310	Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral Neurotoxicity. <i>FASEB Journal</i> , <b>2020</b> , 34, 1-1	0.9	
309	Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors. <i>Pain</i> , <b>2020</b> , 161, 405-415	8	19
308	Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity. <i>Neuropharmacology</i> , <b>2020</b> , 164, 107905	5.5	20
307	Early Stimulation of TREK Channel Transcription and Activity Induced by Oxaliplatin-Dependent Cytosolic Acidification. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
306	Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1306-1319	10.3	62
305	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3325-3348	2.2	168
304	Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	8
303	Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. <i>Expert Review of Neurotherapeutics</i> , <b>2020</b> , 20, 1005-1016	4.3	10
302	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. <i>Nature Communications</i> , <b>2020</b> , 11, 5938	17.4	5
301	The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity. <i>Experimental Neurology</i> , <b>2020</b> , 334, 113458	5.7	2
300	Reply to a Comment Paper on the Published Paper by Canta, A. et al: "Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity"- 2020, , 594. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	1
299	Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 1092-1099	5.5	11

298	Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 136-143	6	15
297	Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 626687	8.4	21
296	Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , <b>2019</b> , 24 Suppl 2, S26-S39	4.7	36
295	Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue. <i>Journal of the Peripheral Nervous System</i> , <b>2019</b> , 24 Suppl 2, S6-S12	4.7	20
294	Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. <i>Endocrine Connections</i> , <b>2019</b> , 8, 1118-1125	3.5	8
293	An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection. <i>Archives of Toxicology</i> , <b>2019</b> , 93, 2835-2848	5.8	10
292	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , <b>2019</b> , 24, 111-119	4.7	11
291	Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2806-2809	1.9	8
290	Anti-tumor Efficacy Assessment of the Sigma Receptor Pan Modulator RC-106. A Promising Therapeutic Tool for Pancreatic Cancer. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 490	5.6	10
289	Anti-Multiple Myeloma Potential of Secondary Metabolites from. <i>Molecules</i> , <b>2019</b> , 24,	4.8	9
288	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 1361-1369	5.5	28
287	Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , <b>2019</b> , 24, 360-361	4.7	4
286	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , <b>2019</b> , 24, 298-303	4.7	9
285	Clinician-rated measures for distal symmetrical axonal polyneuropathy: ACTION systematic review. <i>Neurology</i> , <b>2019</b> , 93, 346-360	6.5	14
284	Global Transcriptomic Profile of Dorsal Root Ganglion and Physiological Correlates of Cisplatin-Induced Peripheral Neuropathy. <i>Nursing Research</i> , <b>2019</b> , 68, 145-155	1.9	4
283	Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity. <i>Current Opinion in Neurology</i> , <b>2019</b> , 32, 676-683	7.1	9
282	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , <b>2019</b> , 40, 155-165	3.5	42
281	Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 125-132	5.5	67

280	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 3143-3151	3.9	12
279	Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)]PF and [Au(P)]PF (P = thp or PTA) Anticancer Complexes. <i>Neurotoxicity Research</i> , <b>2018</b> , 34, 93-108	4.3	6
278	Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. <i>Neurobiology of Disease</i> , <b>2018</b> , 111, 59-69	7.5	38
277	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics</i> , <b>2018</b> , 15, 178-189	6.4	63
276	Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. <i>Experimental Neurology</i> , <b>2018</b> , 307, 129-132	5.7	29
275	Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTION recommendations. <i>Neurology</i> , <b>2018</b> , 91, 403-413	6.5	42
274	High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. <i>Journal of Neuroinflammation</i> , <b>2018</b> , 15, 232	10.1	28
273	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 816-825	15.9	38
272	Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. <i>Cancer Research</i> , <b>2018</b> , 78, 817-829	10.1	38
271	Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 113-121	4	24
270	Comparing the different response of PNS and CNS injured neurons to mesenchymal stem cell treatment. <i>Molecular and Cellular Neurosciences</i> , <b>2018</b> , 86, 16-24	4.8	5
269	The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. <i>Orphanet Journal of Rare Diseases</i> , <b>2018</b> , 13, 176	4.2	14
268	Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models. <i>European Journal of Pharmacology</i> , <b>2018</b> , 840, 89-103	5.3	9
267	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , <b>2018</b> , 141, 2866-2877	11.2	96
266	Oxaliplatin induces pH acidification in dorsal root ganglia neurons. <i>Scientific Reports</i> , <b>2018</b> , 8, 15084	4.9	14
265	Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents. <i>European Journal of Medicinal Chemistry</i> , <b>2018</b> , 158, 353-370	6.8	10
264	ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. <i>Journal of Controlled Release</i> , <b>2017</b> , 249, 103-110	11.7	73
263	Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2017</b> , 171, 229-235	5.1	54

262	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , <b>2017</b> , 22, 68-76	4.7	55
261	Pain in chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , <b>2017</b> , 22, 156-161	4.7	19
260	Are sigma receptor modulators a weapon against multiple sclerosis disease?. <i>Future Medicinal Chemistry</i> , <b>2017</b> , 9, 2029-2051	4.1	11
259	Cerebrospinal fluid analysis and the determination of oligoclonal bands. <i>Neurological Sciences</i> , <b>2017</b> , 38, 217-224	3.5	19
258	Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations. <i>Neurology</i> , <b>2017</b> , 89, 859-869	6.5	28
257	Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. <i>Journal of Pain and Symptom Management</i> , <b>2017</b> , 54, 701-706.e1	4.8	28
256	Microbeam radiation therapy - grid therapy and beyond: a clinical perspective. <i>British Journal of Radiology</i> , <b>2017</b> , 90, 20170073	3.4	41
255	Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). <i>Quality of Life Research</i> , <b>2017</b> , 26, 2999-3010	3.7	36
254	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , <b>2017</b> , 2,	0	3
253	Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study. <i>International Archives of Occupational and Environmental Health</i> , <b>2017</b> , 90, 741-746	3.2	1
252	Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 492-504	15	48
251	Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. <i>Experimental Neurology</i> , <b>2017</b> , 288, 75-84	5.7	16
250	Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. <i>Muscle and Nerve</i> , <b>2017</b> , 55, 366-372	3.4	18
249	Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186250	3.7	39
248	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 5059-5068	3.9	50
247	A phosphotyrosine switch regulates organic cation transporters. <i>Nature Communications</i> , <b>2016</b> , 7, 10880	17.4	74
246	Drugs for the treatment of peripheral neuropathies. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 381-94		12
245	Toward the identification of neuroprotective agents: g-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising SIGMA1 receptor agonist. <i>Future Medicinal Chemistry</i> , <b>2016</b> , 8, 287-95	4.1	23

244 Toxic Neuropathies **2016**, 275-284

243 Severe, reversible nelarabine-induced neuropathy and myelopathy. *Journal of the Peripheral Nervous System*, **2016**, 21, 154-6 4.7 5

242 Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. *Scientific Reports*, **2016**, 6, 28861 4.9 31

241 Antitumoral Effect of Hibiscus sabdariffa on Human Squamous Cell Carcinoma and Multiple Myeloma Cells. *Nutrition and Cancer*, **2016**, 68, 1161-70 2.8 12

240 Age-related changes in the function and structure of the peripheral sensory pathway in mice. *Neurobiology of Aging*, **2016**, 45, 136-148 5.6 21

239 Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 729-34 5.5 57

238 Dihydrotestosterone as a Protective Agent in Chronic Experimental Autoimmune Encephalomyelitis. *Neuroendocrinology*, **2015**, 101, 296-308 5.6 28

237 Platinum-induced neurotoxicity and preventive strategies: past, present, and future. *Oncologist*, **2015**, 20, 411-32 5.7 151

236 Lack of sterol regulatory element binding factor-1c imposes glial Fatty Acid utilization leading to peripheral neuropathy. *Cell Metabolism*, **2015**, 21, 571-83 24.6 36

235 Functional Magnetic Resonance Imaging of Rats with Experimental Autoimmune Encephalomyelitis Reveals Brain Cortex Remodeling. *Journal of Neuroscience*, **2015**, 35, 10088-100 6.6 47

234 Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. *Journal of Steroid Biochemistry and Molecular Biology*, **2015**, 146, 74-9 5.1 55

233 Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: new useful ready-to-use animal models. *Experimental Neurology*, **2015**, 264, 92-102 5.7 20

232 Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. *Journal of the Peripheral Nervous System*, **2015**, 20, 15-23 4.7 28

231 The lipogenic regulator Sterol Regulatory Element Binding Factor-1c is required to maintain peripheral nerve structure and function. *SpringerPlus*, **2015**, 4, L45

230 Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc( ) ) in patients with chemotherapy-induced peripheral neuropathy. *Journal of the Peripheral Nervous System*, **2015**, 20, 328-32 4.7 23

229 Chemotherapy-induced peripheral neurotoxicity. *Current Opinion in Neurology*, **2015**, 28, 500-7 7.1 78

228 Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2015**, e553-60 7.1 30

227 Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats. *Diabetes*, **2015**, 64, 1035-45 5.9 48



226	Calcium-related neurotoxicity of oxaliplatin: understanding the mechanisms to drive therapy. <i>Current Medicinal Chemistry</i> , <b>2015</b> , 22, 3682-94	4.3	12
225	Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2015</b> , 29, 115-24	0.7	4
224	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 392-8	5.5	91
223	A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 1123-33	4.3	11
222	Interventions for preventing neuropathy caused by cisplatin and related compounds. <i>The Cochrane Library</i> , <b>2014</b> , CD005228	5.2	58
221	Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 1085-91	7.1	37
220	Bortezomib-induced peripheral neurotoxicity: an update. <i>Archives of Toxicology</i> , <b>2014</b> , 88, 1669-79	5.8	51
219	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. <i>Journal of the Peripheral Nervous System</i> , <b>2014</b> , 19, 127-35	4.7	26
218	Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1941-67	2.2	788
217	Quantitative detection of epstein-barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e94497	3.7	22
216	Evaluation of tubulin polymerization and chronic inhibition of proteasome as cytotoxicity mechanisms in bortezomib-induced peripheral neuropathy. <i>Cell Cycle</i> , <b>2014</b> , 13, 612-21	4.7	44
215	Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve. <i>BioMed Research International</i> , <b>2014</b> , 2014, 180428	3	40
214	Neuroactive steroid levels in plasma and cerebrospinal fluid of male multiple sclerosis patients. <i>Journal of Neurochemistry</i> , <b>2014</b> , 130, 591-7	6	40
213	Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know. <i>Journal of the Peripheral Nervous System</i> , <b>2014</b> , 19, 66-76	4.7	36
212	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , <b>2014</b> , 25, 257-64	10.3	112
211	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , <b>2014</b> , 19, 299-306	4.7	48
210	Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. <i>Supportive Care in Cancer</i> , <b>2014</b> , 22, 1161-9	3.9	28
209	The combined therapeutical effect of metal-based drugs and radiation therapy: the present status of research. <i>Current Medicinal Chemistry</i> , <b>2014</b> , 21, 2237-65	4.3	41

208	Novel therapeutic targets in neuropsychiatric disorders: the neuroepigenome. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 1831-9	3.3	5
207	Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1175, 301-22	1.4	19
206	Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity. <i>Anticancer Research</i> , <b>2014</b> , 34, 483-6	2.3	21
205	Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B. <i>Anticancer Research</i> , <b>2014</b> , 34, 517-23	2.3	16
204	Synchrotron-based photon activation therapy effect on cisplatin pre-treated human glioma stem cells. <i>Anticancer Research</i> , <b>2014</b> , 34, 5351-5	2.3	6
203	Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. <i>Cancer</i> , <b>2013</b> , 119, 438-44	6.4	142
202	Multimodal analysis in acute and chronic experimental autoimmune encephalomyelitis. <i>Journal of NeuroImmune Pharmacology</i> , <b>2013</b> , 8, 238-50	6.9	12
201	Islet transplantation and insulin administration relieve long-term complications and rescue the residual endogenous pancreatic $\beta$ cells. <i>American Journal of Pathology</i> , <b>2013</b> , 183, 1527-38	5.8	5
200	Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. <i>European Journal of Neurology</i> , <b>2013</b> , 20, 188-92	6	21
199	Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 2598-603	1.1	68
198	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2910-8	7.5	35
197	Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain. <i>Neurological Sciences</i> , <b>2013</b> , 34, 373-7	3.5	30
196	Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue. <i>Pain Management</i> , <b>2013</b> , 3, 417-9	2.3	2
195	Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1418-9	10.3	
194	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Annals of Oncology</i> , <b>2013</b> , 24, 454-462	10.3	191
193	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. <i>Cancer</i> , <b>2013</b> , 119, 3570-7	6.4	69
192	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. <i>European Journal of Neurology</i> , <b>2013</b> , 20, 788-94	6	24
191	Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study. <i>Journal of the Peripheral Nervous System</i> , <b>2013</b> , 18, 19-24	4.7	18

190	Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 11199-204	11.5	125
189	Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. <i>PLoS ONE</i> , <b>2013</b> , 8, e72995	3.7	54
188	Functionalized mesoporous silica nanoparticles: a possible strategy to target cancer cells reducing peripheral nervous system uptake. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 2589-600	4.3	15
187	The effect of Photon Activation Therapy on cisplatin pre-treated human tumour cell lines: comparison with conventional X-ray irradiation. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2013</b> , 27, 477-85	0.7	3
186	Antibody against tumor necrosis factor- $\beta$ reduces bortezomib-induced allodynia in a rat model. <i>Anticancer Research</i> , <b>2013</b> , 33, 5453-9	2.3	17
185	Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 82, 51-77	7	350
184	Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. <i>Lancet Neurology</i> , <b>2012</b> , 11, 493-502	24.1	153
183	Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. <i>Journal of Neuroendocrinology</i> , <b>2012</b> , 24, 851-61	3.8	42
182	Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 340, 64-72	4.7	34
181	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , <b>2012</b> , 23, 3116-3122	10.3	56
180	Neurophysiological examination of dorsal sural nerve. <i>Muscle and Nerve</i> , <b>2012</b> , 46, 895-8	3.4	13
179	Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. <i>Neuro-Oncology</i> , <b>2012</b> , 14 Suppl 4, iv45-54	1	269
178	Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy. <i>NeuroToxicology</i> , <b>2012</b> , 33, 1-7	4.4	22
177	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 70, 899-902	3.5	29
176	CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. <i>Journal of Pain Research</i> , <b>2012</b> , 5, 151-67	2.9	33
175	Exposure-response relationship of the synthetic epothilone sagopilone in a peripheral neurotoxicity rat model. <i>Neurotoxicity Research</i> , <b>2012</b> , 22, 91-101	4.3	2
174	Evaluation and monitoring of peripheral nerve function. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 104, 163-71	3	
173	Tissue distribution of glutamate carboxypeptidase II (GCPII) with a focus on the central and peripheral nervous system. <i>Current Medicinal Chemistry</i> , <b>2012</b> , 19, 1277-81	4.3	8

172	The glutamatergic neurotransmission in the central nervous system. <i>Current Medicinal Chemistry</i> , <b>2012</b> , 19, 1269-76	4.3	43
171	Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 788-98	5	15
170	Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. <i>Journal of Lipid Research</i> , <b>2012</b> , 53, 300-10	6.3	71
169	The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy-induced peripheral neurotoxicity. <i>Italian Journal of Anatomy and Embryology</i> , <b>2012</b> , 117, 75-97		20
168	Expression, distribution and glutamate uptake activity of high affinity-excitatory aminoacid transporters in in vitro cultures of embryonic rat dorsal root ganglia. <i>Neuroscience</i> , <b>2011</b> , 192, 275-84	3.9	6
167	Sex-dimorphic effects of dehydroepiandrosterone in diabetic neuropathy. <i>Neuroscience</i> , <b>2011</b> , 199, 401-9	3.9	17
166	Bortezomib-induced peripheral neuropathy: facts and genes. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 120-1; author reply 121	21.7	4
165	Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1151-61	21.7	94
164	Sex differences in the manifestation of peripheral diabetic neuropathy in gonadectomized rats: a correlation with the levels of neuroactive steroids in the sciatic nerve. <i>Experimental Neurology</i> , <b>2011</b> , 228, 215-21	5.7	22
163	A role for hemopexin in oligodendrocyte differentiation and myelin formation. <i>PLoS ONE</i> , <b>2011</b> , 6, e201737	3.7	23
162	Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?. <i>Oncologist</i> , <b>2011</b> , 16, 1667-8	5.7	12
161	Interventions for preventing neuropathy caused by cisplatin and related compounds. <i>Cochrane Database of Systematic Reviews</i> , <b>2011</b> , CD005228		67
160	Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. <i>Journal of the Peripheral Nervous System</i> , <b>2011</b> , 16, 228-36	4.7	52
159	Opposite effects of interferon- $\gamma$ on new B and T cell release from production sites in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , <b>2011</b> , 240-241, 147-50	3.5	13
158	Epothilone-induced peripheral neuropathy: a review of current knowledge. <i>Journal of Pain and Symptom Management</i> , <b>2011</b> , 42, 931-40	4.8	28
157	In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin) $\square$ <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 1001-8	3.5	21
156	Chemotherapy-induced neuropathy. <i>Current Treatment Options in Neurology</i> , <b>2011</b> , 13, 180-90	4.4	62
155	Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. <i>Molecular Pain</i> , <b>2011</b> , 7, 29	3.4	98

154	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , <b>2011</b> , 77, 1887-95	6.5	59
153	Drug transporters in chemotherapy induced peripheral neurotoxicity: current knowledge and clinical implications. <i>Current Medicinal Chemistry</i> , <b>2011</b> , 18, 329-41	4.3	12
152	Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. <i>Hypertension</i> , <b>2011</b> , 58, 776-83	8.5	75
151	Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. <i>Cancer Research</i> , <b>2011</b> , 71, 3952-62	10.1	76
150	Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair?. <i>Current Stem Cell Research and Therapy</i> , <b>2011</b> , 6, 82-92	3.6	75
149	Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD). <i>Blood</i> , <b>2011</b> , 118, 1821-1821	2.2	
148	Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 11896-901	6.6	66
147	The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. <i>Current Cancer Drug Targets</i> , <b>2010</b> , 10, 670-82	2.8	54
146	Chemotherapy-induced peripheral neurotoxicity. <i>Nature Reviews Neurology</i> , <b>2010</b> , 6, 657-66	15	204
145	NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. <i>Neuroscience Letters</i> , <b>2010</b> , 486, 141-5	3.3	46
144	Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 479-94	7.5	187
143	Diagnostic validity of optic disc and retinal nerve fiber layer evaluations in detecting structural changes after optic neuritis. <i>Ophthalmology</i> , <b>2010</b> , 117, 1256-1264.e1	7.3	17
142	186 CR4056: A NOVEL POTENT ANTI-NOCICEPTIVE AGENT FOR SEVERAL ANIMAL MODELS OF NEUROPATHIC PAIN. <i>European Journal of Pain Supplements</i> , <b>2010</b> , 4, 55-55		
141	Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. <i>Experimental Neurology</i> , <b>2010</b> , 226, 301-9	5.7	79
140	Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 1178-87	1.9	125
139	Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. <i>Neurotoxicity Research</i> , <b>2010</b> , 17, 380-91	4.3	55
138	The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. <i>Neurotoxicity Research</i> , <b>2010</b> , 18, 151-60	4.3	20
137	Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2010</b> , 220, 104-7	3.5	25

136	Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study. <i>Journal of Neuroscience Research</i> , <b>2010</b> , 88, 3171-9	4.4	15
135	Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. <i>European Journal of Pain</i> , <b>2010</b> , 14, 343-50	3.7	78
134	The ventral caudal nerve: a physiologic-morphometric study in three different rat strains. <i>Journal of the Peripheral Nervous System</i> , <b>2010</b> , 15, 140-6	4.7	7
133	Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. <i>Current Medicinal Chemistry</i> , <b>2009</b> , 16, 1315-24	4.3	69
132	Recent development, applications, and perspectives of mesoporous silica particles in medicine and biotechnology. <i>Current Medicinal Chemistry</i> , <b>2009</b> , 16, 3054-63	4.3	45
131	Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. <i>Neurobiology of Disease</i> , <b>2009</b> , 35, 270-7	7.5	29
130	Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. <i>Neurological Sciences</i> , <b>2009</b> , 30, 99-106	3.5	40
129	Regression of diabetic complications by islet transplantation in the rat. <i>Diabetologia</i> , <b>2009</b> , 52, 2653-61	10.3	29
128	Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. <i>Journal of the Peripheral Nervous System</i> , <b>2009</b> , 14, 36-44	4.7	51
127	Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 656-65	7.5	33
126	Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy. <i>Neuroscience</i> , <b>2009</b> , 164, 520-9	3.9	75
125	Role of MAPKs in platinum-induced neuronal apoptosis. <i>NeuroToxicology</i> , <b>2009</b> , 30, 312-9	4.4	79
124	Continuous buprenorphine delivery effect in streptozotocine-induced painful diabetic neuropathy in rats. <i>Journal of Pain</i> , <b>2009</b> , 10, 961-8	5.2	17
123	Chemotherapy-induced peripheral neurotoxicity: how can we improve knowledge?. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 539-40	21.7	9
122	Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis. <i>Molecular Pharmaceutics</i> , <b>2009</b> , 6, 1363-70	5.6	17
121	Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2009</b> , 9, 760-8	3.2	14
120	Peripheral Neurotoxicity of Platinum Compounds <b>2009</b> , 359-364		
119	Neuropathological changes in the peripheral nervous system and spinal cord in a transgenic mouse model of Niemann-Pick disease type A <b>2009</b> , 28, 263-74		4

118	Peripheral neurotoxicity of platinum-based chemotherapy. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 1p following 71; author reply 1p following 71	31.3	21
117	Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , <b>2008</b> , 13, 267-74	4.7	47
116	Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCP11 in the rat peripheral nervous system. <i>Journal of Anatomy</i> , <b>2008</b> , 213, 539-46	2.9	42
115	Neuroactive steroids and peripheral neuropathy. <i>Brain Research Reviews</i> , <b>2008</b> , 57, 460-9		69
114	Actively induced EAE in Lewis rats: characterization of spleen and spinal cord infiltrating lymphocytes by flow cytometry during the course of the disease. <i>Journal of Neuroimmunology</i> , <b>2008</b> , 199, 67-74	3.5	11
113	Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone?. <i>Current Cancer Drug Targets</i> , <b>2008</b> , 8, 266-74	2.8	8
112	Expression of CD38 in human neuroblastoma SH-SY5Y cells. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2008</b> , 21, 97-105	3	2
111	Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?. <i>Current Medicinal Chemistry</i> , <b>2008</b> , 15, 3025-35	4.3	24
110	Exploiting CD38-mediated endocytosis for immunoliposome internalization. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 599-605	2.4	5
109	Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. <i>Frontiers in Bioscience - Landmark</i> , <b>2008</b> , 13, 3506-24	2.8	23
108	Focus on the role of Glutamate in the pathology of the peripheral nervous system. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2008</b> , 7, 348-60	2.6	20
107	Toxic and Drug-Induced Neuropathies <b>2007</b> , 871-883		4
106	A new device to study ex-vivo the effects of extracorporeal photochemotherapy on the immune system. <i>Journal of Photochemistry and Photobiology B: Biology</i> , <b>2007</b> , 88, 68-75	6.7	2
105	Emerging role of mitogen-activated protein kinases in peripheral neuropathies. <i>Journal of the Peripheral Nervous System</i> , <b>2007</b> , 12, 175-94	4.7	23
104	The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. <i>Journal of the Peripheral Nervous System</i> , <b>2007</b> , 12, 210-5	4.7	175
103	Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy. <i>Cellular and Molecular Life Sciences</i> , <b>2007</b> , 64, 1158-68	10.3	52
102	Interventions for preventing neuropathy caused by cisplatin and related compounds. <i>Cochrane Database of Systematic Reviews</i> , <b>2007</b> , CD005228		37
101	Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. <i>Neuroscience</i> , <b>2007</b> , 144, 1293-304	3.9	157

100	Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 710-7	7.5	54
99	Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. <i>Experimental Neurology</i> , <b>2007</b> , 204, 317-25	5.7	189
98	Current status and future prospective of immunointervention in multiple sclerosis. <i>Current Medicinal Chemistry</i> , <b>2006</b> , 13, 2329-43	4.3	10
97	Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2607-12	12.9	79
96	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. <i>Pharmacological Research</i> , <b>2006</b> , 54, 436-41	10.2	42
95	Human platelets express the synaptic markers VGLUT1 and 2 and release glutamate following aggregation. <i>Neuroscience Letters</i> , <b>2006</b> , 404, 262-5	3.3	31
94	The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity. <i>Current Drug Safety</i> , <b>2006</b> , 1, 35-42	1.4	16
93	Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , <b>2006</b> , 11, 135-41	4.7	118
92	Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. <i>Neurological Sciences</i> , <b>2006</b> , 27, 24-32	3.5	36
91	Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study. <i>Neurological Sciences</i> , <b>2006</b> , 27, 190-3	3.5	46
90	Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. <i>Anticancer Research</i> , <b>2006</b> , 26, 1065-70.	7.3	53
89	Low-dose cisplatin protects human neuroblastoma SH-SY5Y cells from paclitaxel-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1439-47	6.1	6
88	Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 1460-6	7.5	101
87	Interventions for preventing neuropathy caused by cisplatin and related compounds <b>2005</b> ,		4
86	Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. <i>Journal of the Peripheral Nervous System</i> , <b>2005</b> , 10, 202-8	4.7	122
85	Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 168, 111-7	3.5	7
84	A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. <i>Neurological Sciences</i> , <b>2005</b> , 26 Suppl 4, S171-3	3.5	9
83	Sport-related peripheral nerve injuries: part 2. <i>Sport Sciences for Health</i> , <b>2005</b> , 1, 61-67	1.3	1



82	Sport-related peripheral nerve injuries: part 1. <i>Sport Sciences for Health</i> , <b>2005</b> , 1, 55-60	1.3	3
81	An unusual transthyretin gene missense mutation (TTR Phe33Val) linked to familial amyloidotic polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2004</b> , 11, 121-4	2.7	5
80	Erythropoietin both protects from and reverses experimental diabetic neuropathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 823-8	11.5	222
79	Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1439-42	10.3	83
78	Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. <i>Neurology</i> , <b>2004</b> , 62, 2291-3	6.5	121
77	Guidelines by the European Federation of Neurological Societies (EFNS) subcommittee for Continuing Medical Education (CME)--modification 2003. <i>European Journal of Neurology</i> , <b>2004</b> , 11, 145-51	6	1
76	RAT in vivo models of taxanes peripheral neurotoxicity following chronic intravenous administration. <i>Journal of the Peripheral Nervous System</i> , <b>2004</b> , 9, 104-104	4.7	1
75	Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , <b>2004</b> , 151, 55-65	3.5	25
74	Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. <i>Journal of Neuro-Oncology</i> , <b>2004</b> , 67, 65-73	4.8	57
73	Chemotherapy-induced peripheral neurotoxicity. <i>Expert Opinion on Drug Safety</i> , <b>2004</b> , 3, 535-46	4.1	36
72	Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2004</b> , 25, 149-57	5.6	72
71	Extracorporeal photochemotherapy reduces the severity of Lewis rat experimental allergic encephalomyelitis through a modulation of the function of peripheral blood mononuclear cells. <i>Journal of Biological Regulators and Homeostatic Agents</i> , <b>2004</b> , 18, 9-17	0.7	6
70	Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. <i>Neurology</i> , <b>2003</b> , 61, 1297-300	6.5	143
69	Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. <i>Neurochemistry International</i> , <b>2003</b> , 42, 419-29	4.4	50
68	Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 5756-67	12.9	128
67	Women with pregnancy-related polymyositis and high serum CK levels in the newborn. <i>Neurology</i> , <b>2002</b> , 58, 482-4	6.5	16
66	Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. <i>European Journal of Cancer</i> , <b>2002</b> , 38, 1832-7	7.5	77
65	Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. <i>Neuroscience Letters</i> , <b>2002</b> , 322, 103-6	3.3	41

64	Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. <i>Anticancer Research</i> , <b>2002</b> , 22, 4199-204	2.3	25
63	Extracorporeal photochemotherapy reduces the incidence of relapses in experimental allergic encephalomyelitis in DA rats. <i>Journal of Neurology</i> , <b>2001</b> , 248, 535-6	5.5	5
62	Distribution Of Paclitaxel Within The Nervous System Of The Rat After Repeated Intravenous Administration. <i>Journal of the Peripheral Nervous System</i> , <b>2001</b> , 6, 61-61	4.7	8
61	Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. <i>European Journal of Cancer</i> , <b>2001</b> , 37, 2457-63	7.5	215
60	Immunomodulating effects of extracorporeal photochemotherapy in rat experimental allergic encephalomyelitis. <i>International Journal of Tissue Reactions</i> , <b>2001</b> , 23, 21-31		4
59	Lipid-free versus lipid-bound P2 protein-induced experimental allergic neuritis: clinicopathological, neurophysiological, and immunological study. <i>Journal of Neuroscience Research</i> , <b>2000</b> , 62, 709-16	4.4	7
58	LIPID-FREE VS. LIPID-BOUND EXPERIMENTAL ALLERGIC NEURITIS IN THE LEWIS RAT. <i>Journal of the Peripheral Nervous System</i> , <b>2000</b> , 5, 36-37	4.7	1
57	Creutzfeldt-Jakob disease with a novel four extra-repeat insertional mutation in the PrP gene. <i>Neurology</i> , <b>2000</b> , 55, 405-10	6.5	35
56	Effect on the peripheral nervous system of systemically administered dimethylsulfoxide in the rat: a neurophysiological and pathological study. <i>Toxicology Letters</i> , <b>2000</b> , 118, 103-7	4.4	45
55	Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. <i>NeuroToxicology</i> , <b>2000</b> , 21, 389-93	4.4	116
54	Chronic axonal sensory and autonomic polyneuropathy without motor involvement: a new 'chronic inflammatory neuropathy?'. <i>European Journal of Neurology</i> , <b>1999</b> , 6, 249-53	6	6
53	Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies. <i>Journal of the Neurological Sciences</i> , <b>1999</b> , 168, 78-84	3.2	62
52	Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. <i>Experimental Neurology</i> , <b>1999</b> , 159, 551-8	5.7	47
51	Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. <i>NeuroToxicology</i> , <b>1999</b> , 20, 883-7	4.4	67
50	Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. <i>Journal of Neuro-Oncology</i> , <b>1998</b> , 36, 31-40	4.8	44
49	Rapidly progressive multifocal motor neuropathy with phrenic nerve paralysis: effect of nocturnal assisted ventilation. <i>Journal of Neurology</i> , <b>1998</b> , 245, 613-6	5.5	21
48	Polyneuropathy due to cobalamin deficiency in the rat. <i>Journal of the Neurological Sciences</i> , <b>1998</b> , 156, 18-29	3.2	30
47	Carboplatin toxic effects on the peripheral nervous system of the rat. <i>Annals of Oncology</i> , <b>1998</b> , 9, 443-7	10.3	61

46	Retinoic acid differentiated SH-SY5Y human neuroblastoma cells: an in vitro model to assess drug neurotoxicity. <i>Anticancer Research</i> , <b>1998</b> , 18, 2477-81	2.3	48
45	Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. <i>Anticancer Research</i> , <b>1998</b> , 18, 3797-802	2.3	23
44	Risk factors for the development of severe cisplatin neurotoxicity. <i>International Journal of Oncology</i> , <b>1997</b> , 11, 365-70	1	1
43	Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 199-206	2.3	37
42	Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. <i>Journal of Neurology</i> , <b>1997</b> , 244, 85-9	5.5	73
41	Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. <i>NeuroToxicology</i> , <b>1997</b> , 18, 137-45	4.4	83
40	Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. <i>Experimental Neurology</i> , <b>1996</b> , 138, 93-104	5.7	63
39	Evaluation of cisplatin neuroprotection by NT-3. <i>Annals of Neurology</i> , <b>1996</b> , 39, 827	9.4	1
38	Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>1996</b> , 6, 415-419	3.5	24
37	Neuroprotectant drugs in cisplatin neurotoxicity. <i>Anticancer Research</i> , <b>1996</b> , 16, 3149-59	2.3	12
36	Cryoglobulinaemic neuropathy: lack of progression in patients with good haematological control. <i>Acta Neurologica Scandinavica</i> , <b>1995</b> , 92, 372-5	3.8	3
35	Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>1995</b> , 5, 81-86	3.5	45
34	Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. <i>Experimental Neurology</i> , <b>1995</b> , 133, 64-72	5.7	133
33	Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. <i>Cancer</i> , <b>1995</b> , 75, 1141-50	6.4	108
32	Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. <i>Cancer</i> , <b>1995</b> , 76, 916-7	6.4	5
31	Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. <i>Journal of Submicroscopic Cytology and Pathology</i> , <b>1995</b> , 27, 417-25		10
30	An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. <i>Histology and Histopathology</i> , <b>1995</b> , 10, 837-45	1.4	28
29	Homozygous hypertrophic hereditary motor and sensory neuropathies. <i>Italian Journal of Neurological Sciences</i> , <b>1994</b> , 15, 5-14		1

28	Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. <i>Annals of Neurology</i> , <b>1994</b> , 36, 416-24	9.4	237
27	Protective effects of glutathione on cisplatin neurotoxicity in rats. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1994</b> , 29, 771-6	4	55
26	Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. <i>In Vivo</i> , <b>1994</b> , 8, 313-6	3	12
25	Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. <i>NeuroToxicology</i> , <b>1994</b> , 15, 701-4	4.4	23
24	Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. <i>Anticancer Research</i> , <b>1994</b> , 14, 1287-92	2.3	23
23	Long-lasting neuropsychological changes after a single high altitude climb. <i>Acta Neurologica Scandinavica</i> , <b>1993</b> , 87, 103-5	3.8	27
22	Clinical and neurophysiologic evaluation of the effect of Cisplatin administration on the motor nerves. <i>International Journal of Oncology</i> , <b>1993</b> , 2, 81-4	1	
21	Antiepileptic drugs and peripheral nerve function: a multicenter screening investigation of 141 patients with chronic treatment. Collaborative Group for the Study of Epilepsy. <i>Epilepsia</i> , <b>1993</b> , 34, 323-31	6.4	15
20	Topology of two DBI receptors in human lymphocytes <b>1993</b> , 52, 1265-1265		11
19	Effects of exposure to low oxygen pressure on the central nervous system. <i>Sports Medicine</i> , <b>1992</b> , 13, 1-7	10.6	8
18	Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. <i>Acta Neuropathologica</i> , <b>1992</b> , 84, 364-71	14.3	120
17	Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. <i>Italian Journal of Neurological Sciences</i> , <b>1992</b> , 13, 643-7		16
16	Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. <i>Cancer</i> , <b>1992</b> , 69, 203-7	6.4	104
15	The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. <i>Journal of Neurology</i> , <b>1991</b> , 238, 371-4	5.5	53
14	Infantile hereditary neuropathy with hypomyelination: report of two siblings with different expressivity. <i>Neuropediatrics</i> , <b>1991</b> , 22, 65-70	1.6	26
13	Effects of repeated administration of low doses of cisplatin on the rat nervous system. <i>International Journal of Tissue Reactions</i> , <b>1991</b> , 13, 151-7		16
12	MRI evaluation of a case of herpes zoster ophthalmicus with delayed contralateral hemiplegia. <i>Italian Journal of Neurological Sciences</i> , <b>1990</b> , 11, 297-300		2
11	Persistent memory impairment after high altitude climbing. <i>International Journal of Sports Medicine</i> , <b>1990</b> , 11, 176-8	3.6	24

10	A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>1990</b> , 53, 886-9	5.5	26
9	Tissue platinum concentrations and cisplatin schedules. <i>Lancet, The</i> , <b>1990</b> , 336, 1003	4.0	33
8	Hemorrhagic infarction: risk factors, clinical and tomographic features, and outcome. A case-control study. <i>Acta Neurologica Scandinavica</i> , <b>1989</b> , 80, 226-31	3.8	35
7	Blood-nerve barrier of endoneural vessels in experimentally-induced hypothyroidism in rats. <i>International Journal of Tissue Reactions</i> , <b>1989</b> , 11, 137-42		
6	Sporadic adult onset distal myopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>1988</b> , 51, 468-95.5		
5	Histological features of nerve fibers and endoneural vessels in a case of Wegener's granulomatosis. <i>European Neurology</i> , <b>1988</b> , 28, 77-80	2.1	1
4	Brain damage after high-altitude climbs without oxygen. <i>Lancet, The</i> , <b>1987</b> , 1, 101	4.0	23
3	Endoneural vessel involvement in hypothyroidism. <i>Italian Journal of Neurological Sciences</i> , <b>1987</b> , 8, 259-64		1
2	Ultrastructural organization of lamina VI of the spinal cord of the cat. <i>Progress in Neurobiology</i> , <b>1985</b> , 24, 293-331	10.9	5
1	Sigma 1 receptor modulators as a new weapon against multiple sclerosis. <i>BioDiscovery</i> , 20, e14565		